CEO Dr Rohan Hockings said, “This Entitlement Offer has created an opportunity for the company to generate human safety and efficacy data for multiple drug candidates with category-leading potential in areas of major unmet patient need."

The US FDA has granted fast-track designation for Neuren's NNZ-2591 for the treatment of Pitt Hopkins syndrome. 

Australian pharmaceutical manufacturing company IDT Australia (ASX:IDT) has reported an 83 per cent increase in revenue for the first half of financial year 2025.

PYC Therapeutics (ASX:PYC) has announced a pro-rata accelerated non-renounceable entitlement offer to eligible shareholders to raise $146 million.

AusBiotech is taking steps to advance gender equity in the life sciences sector by launching the inaugural Women in Life Sciences Leadership Summit.

Clinical-stage drug development company Syntara (ASX:SNT) has announced new findings from a subgroup analysis of 14 patients from the placebo-controlled SOLARIA2 trial.

Axelia Oncology has entered into a clinical supply agreement with Regeneron to study the use of the PBS-listed PD-1 inhibitor LIBTAYO (cemiplimab) with the Australian company's investigative candidate, AXA-042.

Medicinal cannabis company Althea Group Holdings (ASX:AGH) has announced the appointment of Matt Adams as a non-executive director.

AusBiotech has welcomed the release of the Australian Government’s discussion paper on the Strategic Examination of R&D, underscoring the urgent need for reform to bolster the country's innovation ecosystem and global competitiveness.

Antiviral drug development company Island Pharmaceuticals (ASX:ILA) has announced it has completed subject dosing for the Phase 2b treatment arm of the PROTECT clinical trial of ISLA-101 in dengue fever.

Firebrick Pharma (ASX:FRE) has announced that it has executed a license and distribution agreement under which the Fijian company Makans will immediately commence promoting and selling Nasodine Nasal Spray (nasodine) in Fiji and the South Pacific.

EMVision Medical Devices (ASX:EMV) has received central institutional review board ethics approval for its pivotal validation multicentre diagnostic performance trial of the emu brain scanner in the US.

Artrya is a medical technology company that commercialises the patented Salix artificial intelligence platform, which detects key coronary artery disease imaging markers.

CEO and managing director Dr Paul McKenzie said, “CSL delivered a solid result for the first half of the 2025 financial year led by CSL Behring. Strong demand for many of our market-leading therapies has translated into sales growth, particularly in our core Ig franchise. We continue to advance key initiatives to improve gross margin, which is tracking according to our plans."

The call for abstracts has been extended to 21 February. All abstracts should be 200 words and submitted to AusBiotech's communications team.

Australian clinical-stage radiopharmaceutical company AdvanCell has announced an expansion to the scope and breadth of its strategic collaboration with Eli Lilly to research and develop innovative cancer treatments. 

Clinical-stage radiopharmaceutical company Clarity Pharmaceuticals (ASX:CU6) has added a new asset, 64/67Cu-SAR-trastuzumab, into its Targeted Copper Theranostic portfolio.